Renalytix Launches myIntelX
("Renalytix" or the "Company")
Renalytix Launches myIntelX, Providing National Physician Access to KidneyIntelX Testing Platform
myIntelX will be launching in conjunction with KidneyIntelX going live at
The myIntelX portal can streamline ordering and reporting for current testing locations across the country, including CDPHP health plans in
"Virtual capability provided through our myIntelX portal is an important step towards expanding access nationally to the KidneyIntelX proprietary technology," said
"There are over 37 million Americans with chronic kidney disease, which can be largely treatable or event preventable, but only when identified and intervened within its early stages," said
The launch version of the myIntelX portal supports the secure and efficient execution of both test ordering and report delivery of KidneyIntelX. The portal has been designed for scalability using cutting edge platform technology for optimal user experience. Additional features to support provider and patient education and engagement will follow as part of providing the comprehensive, fully integrated KidneyIntelX platform. After a provider registers with myIntelX online, Renalytix will enable training and support through its commercial salesforce and client service professionals to implement and sustain KidneyIntelX testing in independent practices. Renalytix will continue to process all tests through its clinical laboratories, which are built to the most rigorous standards: CLIA certified, ISO certified, CAP accredited and
KidneyIntelX is the only kidney health platform that has received Breakthrough Device Designation from the FDA. KidneyIntelX has secured provider agreements with more than 30 state Medicaid programs and is also covered under various commercial insurance programs.
For further information, please contact:
|
||||
|
Via Walbrook PR |
|||
|
|
|||
Stifel (Nominated Adviser, Joint Broker) |
Tel: 020 7710 7600 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7597 4000 |
|||
|
|
|||
|
|
|||
|
Tel: 020 7933 8780 or renalytix@walbrookpr.com |
|||
|
Mob: 07980 541 893 / 07584 391 303 / 07407 804 654 |
|||
|
|
|||
|
Tel: 415-389-6400 or investors@renalytix.com |
|||
About Kidney Disease
Kidney disease is now recognized as a public health epidemic affecting over 850 million people globally. The
About Renalytix
About KidneyIntelX
KidneyIntelX, is a first-of-kind solution that enables early-stage diabetic kidney disease (DKD) progression risk assessment by combining diverse data inputs, including validated blood-based biomarkers and personalized data from the patient's health record, and employs a proprietary algorithm to generate a unique patient risk score. This patient risk score enables prediction of progressive kidney function decline in DKD, allowing physicians and healthcare systems to optimize the allocation of treatments and clinical resources to patients at highest risk.
Sources
1https://www.cdc.gov/kidneydisease/publications-resources/ckd-national-facts.html
2://www.nicresearch.com/clinical-research-necessary-nephrology/
3 https://optn.transplant.hrsa.gov/
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Examples of these forward-looking statements include statements concerning: the potential benefits, including economic savings, of KidneyIntelX, the potential for KidneyIntelX to receive regulatory approval from the FDA, the commercial prospects of KidneyIntelX, if approved, including whether KidneyIntelX will be successfully adopted by physicians and distributed and marketed, the expected benefits of the myIntelX platform, including potential effects on test volume and access, our expectations regarding reimbursement decisions and the ability of KidneyIntelX to curtail costs of chronic and end-stage kidney disease, optimize care delivery and improve patient outcomes. Words such as "anticipates," "believes," "estimates," "expects," "intends," "plans," "seeks," and similar expressions are intended to identify forward-looking statements. We may not actually achieve the plans and objectives disclosed in the forward-looking statements, and you should not place undue reliance on our forward-looking statements. Any forward-looking statements are based on management's current views and assumptions and involve risks and uncertainties that could cause actual results, performance or events to differ materially from those expressed or implied in such statements. These risks and uncertainties include, among others: that KidneyIntelX is based on novel artificial intelligence technologies that are rapidly evolving and potential acceptance, utility and clinical practice remains uncertain; we have only recently commercially launched KidneyIntelX; and risks relating to the impact on our business of the COVID-19 pandemic or similar public health crises. These and other risks are described more fully in our filings with the
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the